tyrosine has been researched along with Raynaud Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chatterjee, S; Freedman, RR; Furspan, PB | 1 |
| Black, CM; Denton, CP; Frost, MT; Kingdon, EJ; Mani, AR; Moore, KP; Powis, SH | 1 |
1 trial(s) available for tyrosine and Raynaud Disease
| Article | Year |
|---|---|
Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease.
Topics: Adrenergic alpha-Agonists; Adult; Angiotensin II; Arterioles; Brimonidine Tartrate; Cold Temperature; Enzyme Inhibitors; Female; Genistein; Humans; Middle Aged; Phosphorylation; Protein-Tyrosine Kinases; Quinoxalines; Raynaud Disease; Serotonin; Signal Transduction; Skin; Skin Temperature; Tyrosine; Tyrphostins; Vasoconstriction; Vasoconstrictor Agents | 2004 |
1 other study(ies) available for tyrosine and Raynaud Disease
| Article | Year |
|---|---|
Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from scleroderma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Blood Proteins; Chromatography, Gas; Diagnosis, Differential; Female; Humans; Male; Middle Aged; Raynaud Disease; Scleroderma, Systemic; Tyrosine | 2006 |